SCHEMBL19477145

SCHEMBL19477145

CNc1ccnc(Nc2ccc(OC)c(OC[C@H](CN3CCCC3)OC)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 4/20 0.54
EHMT1 Q9H9B1 3/20 0.54
IGF1R P08069 11/20 0.47
SYK P43405 2/20 0.46
CDK1 P06493 2/20 0.42
KDR P35968 2/20 0.42
PLK4 O00444 1/20 0.42
CHEK1 O14757 1/20 0.42
AURKA O14965 1/20 0.42
PDPK1 O15530 1/20 0.42
DAPK3 O43293 1/20 0.42
ROCK2 O75116 1/20 0.42
CHEK2 O96017 1/20 0.42
CSF1R P07333 1/20 0.42
PIM1 P11309 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42
FGFR3 P22607 1/20 0.42
RPS6KB1 P23443 1/20 0.42
CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19477148 1.00 EHMT2 (0.54) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL25610360 1.00 EHMT2 (0.54) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19477070 0.89 EHMT2 (0.54) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19477507 0.89 EHMT2 (0.54) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19477068 0.89 EHMT2 (0.54) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19700679 0.88 EHMT2 (0.53) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19476815 0.88 EHMT2 (0.53) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19476841 0.88 EHMT2 (0.53) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19476519 0.87 EHMT2 (0.52) EHMT2EHMT1IGF1RSYKCDK1
SCHEMBL19476521 0.87 EHMT2 (0.52) EHMT2EHMT1IGF1RSYKCDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442947-B1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS EPIZYME INC (US) 2023-06-07 EP disclosed
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES Epizyme, Inc. 2021-07-15 US disclosed
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2021-07-01 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS Epizyme, Inc. 2017-12-14 US disclosed
WO-2017181177-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS Epizyme, Inc. (US) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355712-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 EHMT2 4/4885EHMT1 7/4885IGF1R 4094/4885
US-20210198277-A1 AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS SHMT1, BHMT, BHMT2 EHMT2 4/4885EHMT1 7/4885IGF1R 4094/4885
US-20210213014-A1 METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES EHMT2, BHMT2, BHMT EHMT2 1/4885EHMT1 4/4885IGF1R 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.